跳至主要内容
临床试验/NCT05053997
NCT05053997招募中不适用

NAVIGATE - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients Through Nurse Navigation, Symptom Monitoring and Exercise: Study Protocol for a Multicenter Randomized Controlled Trial

Zealand University Hospital10 个研究点 分布在 1 个国家目标入组 250 人开始时间: 2022年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
250
试验地点
10
主要终点
A hierarchical composite outcome of survival and global quality of life

研究概览

简要总结

Half of patients with lung cancer face a limited life span of one-year survival, which is characterized by severe physical and psychological symptoms. Differences in stage, comorbidity but also treatment may explain a large proportion of the social inequality in lung cancer survival. Some vulnerable patients may not receive first line treatment as planned either due to poor performance status or if they are not able to adhere to treatment appointments. Knowing how to navigate the health system may be a barrier preventing vulnerable patients in receiving optimal treatment. The primary aim of this randomised, controlled trial is to test whether a nurse-led individually tailored program including systematic screening of symptoms using PROs and a physical training program will significantly improve a composite outcome of survival and quality of life as the primary outcome among vulnerable lung cancer patients compared with standard care. Secondary outcomes include adherence to cancer treatment, symptom burden and overall survival.

详细描述

During a period of 3 years and 10 months, consecutive newly diagnosed (< 1 week) lung cancer patients will be pre-screened for eligibility and invited to participate at departments of oncology or respiratory medicine in Denmark. Participants (N=250) will be randomized (1:1) to standard treatment plus the intervention (intervention group) or standard treatment (control group) and followed for 1 year. Patients randomized to the control group will receive standard treatment and care consisting of a nurse and a physician, who sees the patient at treatment schedules and during follow-up, i.e. every 3 months for the first 2 years and subsequently annually up to 5 years.

Data will be collected from the intervention and the control group at baseline within 6 weeks after diagnosis, and 3, 6 months and 12 months after diagnosis. Physical tests will be performed at baseline and after 3 and 6 months. Baseline physical tests will be allowed after randomization if patients have difficulties in attending the physiotherapy department within 6 weeks after their diagnosis. Considering that participating patients are vulnerable with limited resources we will proactively support patients in responding to questionnaires electronically, on paper or via telephone as per patient's preference allowing evaluation of the primary and secondary outcomes as well as covariates and mechanisms. The treatment factors will be obtained from the lung cancer clinical database and individual medical journals. In order to develop cost utility analyses, information on use of health services will be retrieved from the national registers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years of age
  • Diagnosed with NSCLC at all stages regardless of treatment intension at the participating departments
  • Performance status ≤ 2
  • Vulnerable according to pre-defined criteria

排除标准

  • Severe untreated psychiatric disorder (e.g. psychosis) or cognitive problems (e.g. dementia) preventing informed consent
  • Not able to receive treatment
  • Not able to read and understand Danish -

结局指标

主要结局

A hierarchical composite outcome of survival and global quality of life

时间窗: 3 months from randomization

Measured from death from all causes and the Global Health Status (a subscale of EORTC QLQ-C30)

次要结局

  • Health behavior(12 months from randomization)
  • Self-efficacy and self-activation(12 months from randomization)
  • Rehabilitation services(12 months from randomization)
  • Process evaluation(12 months from evaluation)
  • Cost-effectiveness(12 months from randomization)
  • Overall survival(6 months from randomization)
  • Adherence to cancer treatment(12 months from randomization)
  • Symptom burden and health related quality of life(12 months from randomization)
  • Quality of life (QOL) measured by EuroQol EQ-5D-5L(12 months from randomization)
  • Quality of life (QOL) measured by EuroQol EQ-5D-5L(12 months from randomization)
  • Overall survival(12 months from randomization)
  • Health behavior(12 months from randomization)
  • Adherence to cancer treatment(12 months from randomization)
  • Symptom burden and health related quality of life(12 months from randomization)
  • Self-efficacy and self-activation(12 months from randomization)
  • Rehabilitation services(12 months from randomization)
  • Process evaluation(12 months from evaluation)
  • Cost-effectiveness(12 months from randomization)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Susanne Dalton

Professor, MD, PhD

Zealand University Hospital

研究点 (10)

Loading locations...

相似试验